CCX 282-b, an oral CCR9-specific antagonist, induces high levels of remission in the open-label phase of protect-1 clinical trial in crohn's disease

被引：0
|
作者：
Hetzel, D. J. [1 ]
Gibson, P. R. [1 ]
Radford-Smith, G. [1 ]
Macrae, F. [1 ]
Bekker, P. [1 ]
Schall, T. J. [1 ]
机构：
[1] Royal Adelaide Hosp, Adelaide, SA, Australia
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2008年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A190 / A190
页数：1
相关论文
共 8 条
  • [1] Traficet-EN, an Oral CCR9-Specific Antagonist, induces high levels of remission in the open-label Phase of PROTECT-1 in Crohn's Disease
    Bekker, P.
    Johnson, D.
    Hamilton, G.
    Keshav, S.
    Schall, T.
    INFLAMMATORY BOWEL DISEASES, 2008, 14 (12) : S24 - S24
  • [2] Traficet-EN, an oral CCR9-specific antagonist, induces high levels of remission in the open-label phase of PROTECT-1 in Crohn's disease
    Bekker, Pirow
    Hamilton, Gordon
    Johnson, Dan
    Keshav, Satish
    Schall, Thomas
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 : S409 - S409
  • [3] Chemokine Receptor Antagonist CCX282-B (Traficet-En™) Maintained Remission of Crohn's Disease in PROTECT-1 Study
    Keshav, Satish
    Johnson, Daniel
    Schall, Thomas
    Bekker, Pirow
    GASTROENTEROLOGY, 2010, 138 (05) : S86 - S86
  • [4] Protect-1, a prospective randomized oral therapy evaluation of CCX282-B (Traficet-EN) in Crohn's disease trial
    Bekker, P.
    Petryka, R.
    Vanasek, T.
    Niv, Y.
    Marlicz, K.
    Haagen-Nielsen, O.
    Dahelrup, J.
    Dotan, I
    Compel, V
    Keshav, S.
    Schall, T.
    INFLAMMATORY BOWEL DISEASES, 2008, 14 (01) : S11 - S11
  • [5] PROTECT-1:: A prospective randomized trial of CCX282-B (Traficet-EN), a novel oral therapy targeting chemokine receptor 9 in Crohn's disease
    Keshav, Satish
    Petryka, Robert
    Vanask, Tomas
    Niv, Yaron
    Marlicz, Krzysztof
    Haagen-Nielsen, Ole
    Machado, Marta
    Dahlerup, Jens
    Schreiber, Stefan
    Bekker, Pirow
    Sankar, Sujata
    Schall, Thomas J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 : S475 - S475
  • [6] One-year results from protect-1 study of intestine-specific chemokine receptor antagonist CCX282-B in Crohn's disease
    Williamson, K. D.
    Hetzel, D. J.
    Badov, D.
    Connell, W.
    Edwards, S.
    Gibson, P. R.
    Leong, R. W. L.
    Macrae, F.
    Mitchell, B.
    Radford-Smith, G.
    Bekker, P.
    Schall, T. J.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2010, 25 : A96 - A96
  • [7] PROTECT-1 Maintenance Phase Study Results demonstrate efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Crohn's Disease
    Bekker, P.
    Keshav, S.
    Johnson, D.
    Schall, T.
    INFLAMMATORY BOWEL DISEASES, 2009, 15 (12) : S11 - S11
  • [8] PROTECT-1 Study Demonstrated Efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Treatment of Patients with Moderate to Severe Crohn's Disease
    Keshav, Satish
    Johnson, Daniel
    Bekker, Pirow
    Schall, Thomas J.
    GASTROENTEROLOGY, 2009, 136 (05) : A65 - A65
1